Salarius Pharmaceuticals Inc (SLRX)

Jun 18, 2025

Salarius Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:SLRX - Benzinga

Jun 18, 2025

Jun 17, 2025

What's Going On With Salarius Pharmaceuticals Shares Today? - Benzinga

Jun 17, 2025

Jun 17, 2025

Salarius Granted Nasdaq Extension To Regain Compliance With Listing Standards - Nasdaq

Jun 17, 2025

Jun 16, 2025

Salarius Pharmaceuticals Granted Nasdaq Compliance Extension - TipRanks

Jun 16, 2025

Jun 11, 2025

Salarius Pharmaceuticals adjusts merger terms amid market shifts By Investing.com - Investing.com Nigeria

Jun 11, 2025

Jun 11, 2025

Salarius Pharmaceuticals adjusts merger terms amid market shifts - Investing.com Australia

Jun 11, 2025

Jun 11, 2025

Salarius Pharmaceuticals Enters Second Amendment To Merger Agreement With DecoySEC Filing - MarketScreener

Jun 11, 2025

Jun 08, 2025

Comparing Schrödinger (NASDAQ:SDGR) & Salarius Pharmaceuticals (NASDAQ:SLRX) - Defense World

Jun 08, 2025

Jun 06, 2025

At a crossroads, biotechs are passing on reverse mergers in 2025 - Endpoints News

Jun 06, 2025

May 27, 2025

Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight - GlobeNewswire Inc.

May 27, 2025

May 15, 2025

Salarius: Q1 Earnings Snapshot - New Haven Register

May 15, 2025

May 07, 2025

Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 2.1% – Here’s Why - Defense World

May 07, 2025

Apr 30, 2025

Financial Analysis: Hepion Pharmaceuticals (NASDAQ:HEPA) versus Salarius Pharmaceuticals (NASDAQ:SLRX) - Defense World

Apr 30, 2025

Apr 27, 2025

Closing Figures Unveiled: Salarius Pharmaceuticals Inc (SLRX) Drop -26.34, Closes at 0.60 - DWinneX

Apr 27, 2025

Apr 26, 2025

Salarius Pharmaceuticals faces Nasdaq delisting over rule breaches By Investing.com - Investing.com Canada

Apr 26, 2025

Apr 25, 2025

Salarius Pharmaceuticals faces Nasdaq delisting over rule breaches - Investing.com

Apr 25, 2025

Apr 16, 2025

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Robert S. Langer To Scientific Advisory Board - citybiz

Apr 16, 2025

Apr 16, 2025

Decoy Therapeutics to Welcome MIT's Robert Langer to Advisory Board Post-Merger with Salarius (SLRX) | SLRX Stock News - GuruFocus

Apr 16, 2025

Apr 16, 2025

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board - The Manila Times

Apr 16, 2025

Apr 16, 2025

Moderna Co-Founder and MIT Legend Strengthens Decoy Therapeutics Drug Development Team - Stock Titan

Apr 16, 2025

Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Apr 15, 2025

Apr 09, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Apr 09, 2025

Apr 02, 2025

SLRX stock touches 52-week low at $0.7 amid sharp annual decline - Investing.com Canada

Apr 02, 2025

Apr 02, 2025

SLRX stock touches 52-week low at $0.7 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 02, 2025

Apr 01, 2025

Contrasting Salarius Pharmaceuticals (NASDAQ:SLRX) & ASLAN Pharmaceuticals (NASDAQ:ASLN) - Defense World

Apr 01, 2025

Mar 29, 2025

Salarius Amends Merger Terms, Faces Nasdaq Compliance Issue By Investing.com - Investing.com India

Mar 29, 2025

Mar 28, 2025

Salarius Amends Merger Terms, Faces Nasdaq Compliance Issue - Investing.com

Mar 28, 2025

Mar 27, 2025

Decoy Therapeutics’ antiviral candidates show broad activity against multiple viruses - BioWorld MedTech

Mar 27, 2025

Mar 26, 2025

SLRX stock touches 52-week low at $0.83 amid market challenges By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

SLRX stock touches 52-week low at $0.83 amid market challenges - Investing.com Australia

Mar 26, 2025

Mar 26, 2025

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related Viruses - MarketScreener

Mar 26, 2025

Mar 26, 2025

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses - GlobeNewswire

Mar 26, 2025

Mar 26, 2025

Revolutionary AI Platform Discovers Multi-Target Antiviral in Just 5 Days - Stock Titan

Mar 26, 2025

Mar 24, 2025

Salarius Pharmaceuticals Advances Merger with Decoy Therapeutics to Enhance Development of Innovative Cancer and Viral Therapeutics - Nasdaq

Mar 24, 2025

Mar 24, 2025

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 24, 2025

Mar 21, 2025

Salarius Pharmaceuticals Inc. (SLRX) reports earnings - Quartz

Mar 21, 2025

Mar 21, 2025

Salarius Pharmaceuticals, Inc. SEC 10-K Report - TradingView

Mar 21, 2025

Mar 19, 2025

Apraxia Treatment Market Size in 7MM is expected to grow at - openPR.com

Mar 19, 2025

Mar 13, 2025

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Update - Defense World

Mar 13, 2025

Mar 12, 2025

SLRX stock touches 52-week low at $0.9 amid market challenges - Investing.com

Mar 12, 2025

Mar 12, 2025

SLRX stock touches 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa

Mar 12, 2025

Mar 11, 2025

Salarius Pharmaceuticals announces registered share offering By Investing.com - Investing.com South Africa

Mar 11, 2025

Mar 11, 2025

Salarius Pharmaceuticals announces registered share offering - Investing.com

Mar 11, 2025